Navigation Links
Planarian genes that control stem cell biology identified
Date:3/1/2012

y into seeking general principles that all animals utilize. I'd say we're at the beginning of that process."

Planarians (Schmidtea mediterranea) are tiny freshwater flatworms with the ability to reproduce through fission. After literally tearing themselves in half, the worms use stem cells, called cNeoblasts, to regrow any missing tissues and organs, ultimately forming two complete planarians in about a week.

Unlike muscle, nerve, or skin cells that are fully differentiated, certain stem cells, such as cNeoblasts and embryonic stem cells are pluripotent, having the ability to become almost cell type in the body. Researchers have long been interested in harnessing this capability to regrow damaged, diseased, or missing tissues in humans, such as insulin-producing cells for diabetics or nerve cells for patients with spinal cord injuries.

Several problems currently confound the therapeutic use of stem cells, including getting the stem cells to differentiate into the desired cell type in the appropriate location and having such cells successfully integrate with surrounding tissues, all without forming tumors. To solve these issues, researchers need a better understanding of how stem cells tick at the molecular level, particularly within the environment of a living organism. To date, a considerable amount of embryonic stem cell research has been conducted in the highly artificial environment of the Petri dish.

With its renowned powers of regeneration and more than half of its genes having human homologs, the planarian seems like a logical choice for this line of research. Yet, until now, scientists have been unable to efficiently find the genes that regulate the planarian stem cell system.

Postdoctoral researcher Dan Wagner, first author of the Cell Stem Cell paper, and Reddien devised a clever method to identify potential genetic regulators and then determine if those genes affect the two main functions of stem
'/>"/>

Contact: Nicole Giese Rura
rura@wi.mit.edu
617-258-6851
Whitehead Institute for Biomedical Research
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. 2 genes do not make a voter
2. In the genes, but which ones?
3. Fused genes tackle deadly Pierces disease in grapevines
4. Genes may travel from plant to plant to fuel evolution
5. Synthetic protein amplifies genes needed for stem cells
6. Using plants to silence insect genes in a high-throughput manner
7. Same genes linked to early- and late-onset Alzheimers
8. UCSF shares $25-million grant to find epilepsy genes
9. Research team discovers genes and disease mechanisms behind a common form of muscular dystrophy
10. 2 genes affect anxiety, behavior in mice with too much MeCP2
11. Study of skates and sharks questions assumptions about essential genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... common and deadly form of primary malignant brain cancer ... occurring mostly in adults between the ages of 45 ... cancer is only temporarily contained by combined surgery, chemotherapy ... fatal, resulting in an average patient survival time of ...
... passing from hand to hand, falling on streets and sidewalks, ... and sends it to the shredder. Rather than destroying it, ... to prolong its life. The research, which appears in the ... save billions and minimize the environmental impact of banknote disposal. ...
... Previous studies have established that carbon binds to tiny mineral ... , researchers have shown that the surface of the minerals ... carbon binds to minerals that are just a few thousandths ... almost exclusively on rough and angular surfaces," explains Prof. Ingrid ...
Cached Biology News:Stopping tumors in their path 2
(Date:5/4/2015)... Genedata, a leading provider of advanced ... research, today announced the release of Genedata ... enterprise solution for biologics R&D. This first-in-class workflow ... and development of novel biotherapeutics. Version 5.0 enables ... optimization and developability requirements. Genedata will present highlights ...
(Date:5/4/2015)... 4, 2015 China Cord Blood Corporation (NYSE: ... China,s leading provider of cord blood collection, ... storage services, today announced that the Company has been ... Hong Kong listed company and ... an agreement (the "Agreement") to purchase the Company,s outstanding ...
(Date:5/4/2015)... 2015   Intrexon Corporation (NYSE: XON ... financial results after the market closes on May 11, ... day at 5:30 PM ET to discuss the results ... conference call may be accessed by dialing 1-888-346-3959 (Domestic ... "Intrexon Conference Call."  Participants may also access the live ...
(Date:5/1/2015)... , May 1, 2015  Northwest Biotherapeutics (NASDAQ: ... DCVax® personalized immune therapies for solid tumor cancers, announced ... million second tranche of a $40 million investment from ... Woodford first invested $25 million in NW Bio on ... into an agreement with the Company for a further ...
Breaking Biology Technology:Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3
... 0641-2450-45 and 0641-2450-41;, LOTS: 107054, 117085, 047056, 097081, 107024, 107064, ... ... DEERFIELD, Ill., Jan. 25 Baxter Healthcare,Corporation has announced the voluntary recall ... vials. The company,began recalling the lots on January 17, 2008 as a ...
... DIEGO, Jan. 25 NuVasive, Inc. (Nasdaq:,NUVA), a medical ... treatments for the spine, announced today,details relating to its ... take place on Tuesday, February 19, 2008, after,the close ... call on Tuesday, February 19, 2008 at,5:30 p.m. ET ...
... 25 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced ... clinical trial of a second generation oral niacin receptor ... for the,treatment of atherosclerosis and other disorders. The initiation ... "We are very pleased with the progress of this ...
Cached Biology Technology:Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials 2NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 2NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 3Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 3
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
...
... The SelectFX Alexa Fluor 488 Cytochrome c ... you need to detect cytochrome c in ... c primary antibody and an Alexa ... 488 dye exhibits bright green fluorescence that ...
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
Biology Products: